Abstract-The present study was designed to examine and compare the acute effects of lisinopril (20 mg) and enalapril (10 mg) after a single oral administration on the inhibition of the renin-angiotensin system (RAS) in eight normal subjects. Serum concentration of lisinopril and enalaprilat, an active metabolite of enalapril, reached the respective maximal levels at 6 and 4 hr after administration of the drugs. At 24 hr, the serum concentration of lisinopril was higher than that of enalapril; thus the rate of disappearance of lisinopril was retarded, in comparison to that of enalapril.
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The reduction of serum angiotensin I converting enzyme (ACE) activity was consistent with the pattern of increase of concentration of the drugs in the serum.
However, with these two drugs, the concentration of plasma ANG II was decreased in a similar manner, and it returned to the pretreatment level within 24 hr. Thus, there was no significant difference in ANG II levels throughout the 24 hr study between the lisinopril and enalapril treatment.
The results indicate that a single administration of 20 mg lisinopril and 10 mg enalapril show similar potency for lowering the circulating ANG II level, although lisinopril exerts a more sustained inhibition of serum ACE activity.
The measurement of ANG II provides useful informations for evaluating the efficacy of ACE inhibitors for the inhibition of circulatory RAS.
Angiotensin
I-converting enzyme (ACE) inhibitors have been clinically used as the first choice for treatment of hypertension (1 ). It is considered that the pharmacodynamic action is mainly due to the inhibition of the renin-angiotensin system (RAS) (2). Al though inhibition of ACE activity in the plasma has been conventionally used to estimate the extent of RAS blockade in the circulation, the change of ACE activity does not correlate with the blood lowering effect by ACE in hibitors (3-5). The ACE activity in the plasma provides limited information as a parameter for the activity of circulatory RAS. In the plasma, not only ACE, but also ANG I concen tration contributes as a limiting factor for the production of ANG II. Nussberger (6) dem onstrated that the concentration of plasma ANG II correlated with that of plasma ANG I under ACE inhibition, supporting the conten tion that ANG I is one of the determinants of plasma ANG II levels.
Accurate measurement of plasma ANG II levels is difficult because its concentration is very low (7), and the antibody raised against ANG II cross-reacts with ANG I and a variety of ANG II metabolites (8). Recently, the sensitivity and specificity for quantification of ANG II have been improved by using Sep-Pak extraction and HPLC separation (9, 10), and this method has made it possible to estimate accurate ANG II levels.
Lisinoprii (10) and enalapril (11) are both long acting drugs and maintain their hy potensive action with oral administration once a day. Lisinopril is a lysine analogue of enalaprilat which is an active metabolite of enalapril (12). Although both drugs have physico-chemical properties (12) and in hibitory kinetics that are similar to ACE in vitro (13) and in vivo (14), lisinopril differs from enalapril in that it is absorbed more slowly than enalapril, and it requires no bioac tivation (15). These differences may affect the time course of plasma ANG II levels after the drug administration.
In the present study, the selected dose of lisinopril (20 mg) was twice that of enalapril (10 mg), because the clini cally recommended dose of lisinopril for patients with no complications ranges be tween 20-80 mg/day (16), while enalapril is used in a dose range between 10-40 mg/day (17). The present study was designed to examine and compare the effects of the two drugs on the time course of ANG II and other components of RAS during the 24 hr after a single administration.
Materials and Methods
Eight healthy, normotensive volunteers (age: 32±1 years, body weight: 68±3 kg) participated in the study. The nature of the experiment was explained to each subject, and their written informed consents were ob tained. The subjects were maintained on a fixed metabolic diet throughout the study. Meals were given at 08:00, 12:00 and 18:00 hr. Subjects arrived at the Shionogi Biome dical Laboratory by 07:00 hr. Blood was drawn prior to drug administration at 09:00 hr (time 0) and 2, 4, 6, 8, 12, 24 hr later. At each time, the subjects were kept for 30 min in the recumbent position before blood sampling.
Capsules containing 20 mg of lisinopril or 10 mg of enalapril were prepared by the manufacturer.
A single capsule was administered orally with 1 50 ml of tap water at 09:00 hr. Each subject received both com pounds at an interval of 2 months in a single blind crossover fashion. Plasma concentra tions of ANGs I and II were measured with an extraction system that used a Sep-Pak column followed by HPLC and the RIA reported pre viously (9, 10). A commercial kit was used to assay serum ACE activity (Fujirebio, Ltd., Tokyo) (18). The serum drug concentrations of enalaprilat and lisinopril were measured by RIA (19). For determination of plasma renin activity (PRA), plasma was mixed with an equal volume of citrate-NaOH buffer (50 mM, pH 5.5) containing 20 mM EDTA, 0.5 mM diisopropyl-sulfonyl fluoride, 4.8 mM dimer caprol and 2.4 mM 8-hydroxyquinoline sul fate. Half of the mixture was incubated for 30 or 60 min at 37°C and half was kept at 4°C; the generated ANG I was assayed by radioim munoassay (20) . The plasma concentration of angiotensinogen was determined as pre viously reported (21 ) . All values were ex pressed as the mean±S.E. One-way analysis of variance was performed to determine the effects of the over time on the measured variables. Dunnett's test was used to assess the significance of differences. Two-way analysis of variance was performed to com pare the data of the lisinopril and the en alapril-administered groups at the same time points. Bonferroni's test was used to assess the significance of differences. Linear regres sion analysis and the correlation coefficient were calculated by the method of least squares.
Difference and correlation coef ficients were considered statistically signifi cant when P<0.05. Figure 1 shows the time course changes of drug concentrations of enalaprilat and lisino pril. The enalaprilat reached its peak at the 4th hr and almost disappeared after 24 hr. The concentration change of lisinopril was similar to that of enalaprilat until 4 hr, but reached its peak at 6 hr and remained at 20% of the peak concentration after 24 hr. Table 1 indicated the time course changes of ACE activity, PRA, ANG I, ANG II, and angiotensinogen after administration of lisinopril or enalapril. With lisinopril and enalapril, ACE activity was significantly re duced from the 2nd to 1 2th hr after the drug administration, and the activity was still in hibited in the lisinopril treated group after 24 hr while the activity returned to the pretreat ment value in case of enalapril (table 1). These differences were significant at 8-24 hr (P<0.05), when the lisinopril and the enalapril-administered groups were com pared at the same time points. The maximal inhibitions of ACE activity after lisinopril and enalapril intakes were 94±9% and 84±7% of the pretreatment level, respectively.
Results
By each drug intake, ANG II levels were suppressed, and the concentration of ANG II returned to the pretreatment value after 24 hr. Lisinopril had a tendency to be more potent than enalapril in lowering plasma ANG II levels, although a statistically significance difference was not observed at all time points. The maximal inhibition after lisinopril and enalapril intakes were 78+7% and 64+6% of the pretreatment level, respectively. . The correlation coefficients were derived from 48 points obtained between 2 and 24 hr. The correlation coefficient was 0.89 between the serum levels of lisinopril and the percent inhibition of serum ACE activity after lisinopril intake. The correlation coefficient was 0.90 between the serum levels of enalaprilat and the percent inhibition of serum ACE activity after enalapril intake. These values were statistically significant (P 0.01 ).
PRA and ANG I increased by administra tion of both drugs and the increase by lisino pril was more than that by enalapril (Table 1) . After 24 hr the PRA and ANG I values in creased to 5 times and 2 times the respective pretreatment values in the lisinopril and enalapril treated groups, respectively. How ever, these differences between the two drug administrations were significant only at 12 hr in PRA (P<0.05). Although the concentration of angio tensinogen was not changed significantly after either drug intake, there was a tendency for the concentration to fall with time. Figure 2 shows the relationship between drug concentration and ACE activity. Signifi cantly inverse correlations were observed be tween lisinopril concentration and percent in hibition of ACE activity (r=0.89, P<0.01) and between enalaprilat concentration and per cent inhibition of ACE activity (r=0.90, P< 0.01). Figure 3 shows the relationship between PRA and ANG I concentration. Significant correlations were observed in both lisinopril (r=0.93, P<0.01) and enalapril (r=0.80, P<0.01) administration.
Discussion
The present study carried out to compare the effects of two ACE inhibitors on circula tory PRS. The inhibition of ACE activity in the serum was more persistent with lisinopril than with enalapril. This result corresponded to that reported by Hodsmam et al. (22) . The sustained inhibition of ACE by lisinopril is based on the maintenance of the higher drug concentration after the drug intake as was evident in Fig. 1 . Indeed, the ACE activity was inversely correlated with the concentrations of lisinopril and enalaprilat (Fig. 2) . This is consistent with the contention that lisinopril has a more sustained efficacy for RAS blockade than enalapril. However, meas urement of ANG II demonstrated that the two ACE inhibitors showed similar patterns of time course change and levels of ANG II at all time points. Thus, lisinopril and enalapril showed a similar potency for inhibition of RAS in the circulation at least with the doses used in the present study. This clearly in dicates that when the role of circulating ANG II is evaluated for some pharmacodynamic actions by ACE inhibitors, serum ACE activity can not be an indicator for evaluating the RAS blockade, but measurement of circulat ing ANG II is essential.
The difference of patterns of ACE inhibition and ANG II concentration is probably due to the fact that plasma II level is determined not only by ACE activity, but ANG I concentration affects the ANG II concentration.
The Km (Michaelis-Menten constant) value for ACE is 30 nmol/ml (23), and this value is ap proximately one thousand times the concen tration of plasma ANG I. Therefore, the en hanced concentration of ANG I as a result of ACE inhibition is also determinant of ANG II production, provided that ACE is not com pletely inhibited.
Indeed, elevated ANG I levels by ACE inhibitors seem to cause the difference in patterns of ACE inhibition and ANG II concentration.
The concentration of ANG I increased linearly with the elevated PRA (Fig. 3) . PRA is determined by the concentration of plasma angiotensinogen and enzymatic activity of renin in the plasma. As the angiotensinogen level was maintained at a similar level during 24 hr (Table 1 ) , a change of PRA indicates a change in the enzymatic activity of renin. The increased PRA seems to be attributable to the reduction in ANG II, a potential factor in the feedback mechanism of renin release. Twenty four hours after lisinopril administration, PRA remained significantly elevated above the basal value, although the ANG II level re turned to the basal value. Although we do not know the mechanism for the increase in PRA, it may be explainable by "tissue" RAS (2, 24). Several investigators (25, 26) reported that when ACE inhibitors are administered, tissue ACE activity is still inhibited although plasma ACE activity returned to the pretreatment level in animal experiments.
The ANG II level around the juxta-glomerular cells might have been kept at a low level even when plasma ANG II level returned to the pretreatment level. The low level of ANG II around the juxta-glomerular cells might have stimulated renin release. Further studies are required to elucidate the mechanism, for example, we must determine the locally generated ANG II level.
In conclusion, we indicated that a single administration of 20 mg lisinopril and 10 mg enalapril show similar potency for lowering the circulating ANG II level, although lisino pril exerts a more sustained inhibition of serum ACE activity. The measurement of ANG II provides useful information for evaluating the efficacy of ACE inhibitors for inhibition of circulatory RAS.
